# Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

> **NCT01585194** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Uveal Melanoma
- Stage IV Uveal Melanoma AJCC v7

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT01585194
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-29
- **Primary completion:** 2019-12-02
- **Final completion:** 2024-05-14
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01585194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01585194, "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01585194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*